Race Oncology Limited
OTC: RAONF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Tillett
- Headquarters
- Sydney, Australia
- IPO year
- 2021
- Market cap
- $451.7M
- Website
- https://www.raceoncology.com
Loading RAONF…
Loading profile data…Frequently asked questions about RAONF
What does Race Oncology Limited (RAONF) do?
Based in Sydney, Australia, Race Oncology Limited is an Australian precision oncology firm that commenced operations in 2011. The company's primary focus is the development of Zantrene, a potent small molecule designed to inhibit the fatso/fat mass and obesity associated protein (FTO). This therapeutic agent is currently in Phase II/III clinical...
Where does RAONF trade?
Race Oncology Limited (RAONF) trades on the Other OTC.
What sector is RAONF in?
Race Oncology Limited (RAONF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Race Oncology Limited?
Daniel Tillett is the chief executive officer of Race Oncology Limited (RAONF).
Where is Race Oncology Limited headquartered?
Race Oncology Limited is headquartered in Australia.
Does RAONF pay a dividend?
Race Oncology Limited (RAONF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RAONF go public?
Race Oncology Limited (RAONF) completed its initial public offering in 2021.